External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer

Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

Kazuhiko Ogawa, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, Masahiko Koizumi, Yoshiyuki Shioyama, Masayuki Araya, Nobutaka Mukumoto, Michihide Mitsumori, Teruki Teshima

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To analyze retrospectively the results of external beam radiotherapy for clinically localized hormone-refractory prostate cancer and investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcomes after radiotherapy. Methods and Materials: Eighty-four patients with localized hormone-refractory prostate cancer treated with external beam radiotherapy were retrospectively reviewed. The total radiation doses ranged from 30 to 76 Gy (median, 66 Gy), and the median follow-up period for all 84 patients was 26.9 months (range, 2.7-77.3 months). Results: The 3-year actuarial overall survival, progression-free survival (PFS), and local control rates in all 84 patients after radiotherapy were 67%, 61%, and 93%, respectively. Although distant metastases and/or regional lymph node metastases developed in 34 patients (40%) after radiotherapy, local progression was observed in only 5 patients (6%). Of all 84 patients, the median nPSA12 in patients with clinical failure and in patients without clinical failure was 3.1 ng/mL and 0.5 ng/mL, respectively. When dividing patients according to low (<0.5 ng/mL) and high (≥0.5 ng/mL) nPSA12 levels, the 3-year PFS rate in patients with low nPSA12 and in those with high nPSA12 was 96% and 44%, respectively (p < 0.0001). In univariate analysis, nPSA12 and pretreatment PSA value had a significant impact on PFS, and in multivariate analysis nPSA12 alone was an independent prognostic factor for PFS after radiotherapy. Conclusions: External beam radiotherapy had an excellent local control rate for clinically localized hormone-refractory prostate cancer, and nPSA12 was predictive of clinical outcomes after radiotherapy.

Original languageEnglish
Pages (from-to)759-765
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume74
Issue number3
DOIs
Publication statusPublished - Jul 1 2009

Fingerprint

hormones
antigens
refractories
Prostate-Specific Antigen
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Hormones
progressions
Disease-Free Survival
metastasis
Neoplasm Metastasis
lymphatic system
pretreatment
Multivariate Analysis
Survival Rate
Lymph Nodes
Radiation
dosage

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer : Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months. / Ogawa, Kazuhiko; Nakamura, Katsumasa; Sasaki, Tomonari; Onishi, Hiroshi; Koizumi, Masahiko; Shioyama, Yoshiyuki; Araya, Masayuki; Mukumoto, Nobutaka; Mitsumori, Michihide; Teshima, Teruki.

In: International Journal of Radiation Oncology Biology Physics, Vol. 74, No. 3, 01.07.2009, p. 759-765.

Research output: Contribution to journalArticle

Ogawa, Kazuhiko ; Nakamura, Katsumasa ; Sasaki, Tomonari ; Onishi, Hiroshi ; Koizumi, Masahiko ; Shioyama, Yoshiyuki ; Araya, Masayuki ; Mukumoto, Nobutaka ; Mitsumori, Michihide ; Teshima, Teruki. / External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer : Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 74, No. 3. pp. 759-765.
@article{2a61a53f17ca4c7cb730e08026cb9804,
title = "External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months",
abstract = "Purpose: To analyze retrospectively the results of external beam radiotherapy for clinically localized hormone-refractory prostate cancer and investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcomes after radiotherapy. Methods and Materials: Eighty-four patients with localized hormone-refractory prostate cancer treated with external beam radiotherapy were retrospectively reviewed. The total radiation doses ranged from 30 to 76 Gy (median, 66 Gy), and the median follow-up period for all 84 patients was 26.9 months (range, 2.7-77.3 months). Results: The 3-year actuarial overall survival, progression-free survival (PFS), and local control rates in all 84 patients after radiotherapy were 67{\%}, 61{\%}, and 93{\%}, respectively. Although distant metastases and/or regional lymph node metastases developed in 34 patients (40{\%}) after radiotherapy, local progression was observed in only 5 patients (6{\%}). Of all 84 patients, the median nPSA12 in patients with clinical failure and in patients without clinical failure was 3.1 ng/mL and 0.5 ng/mL, respectively. When dividing patients according to low (<0.5 ng/mL) and high (≥0.5 ng/mL) nPSA12 levels, the 3-year PFS rate in patients with low nPSA12 and in those with high nPSA12 was 96{\%} and 44{\%}, respectively (p < 0.0001). In univariate analysis, nPSA12 and pretreatment PSA value had a significant impact on PFS, and in multivariate analysis nPSA12 alone was an independent prognostic factor for PFS after radiotherapy. Conclusions: External beam radiotherapy had an excellent local control rate for clinically localized hormone-refractory prostate cancer, and nPSA12 was predictive of clinical outcomes after radiotherapy.",
author = "Kazuhiko Ogawa and Katsumasa Nakamura and Tomonari Sasaki and Hiroshi Onishi and Masahiko Koizumi and Yoshiyuki Shioyama and Masayuki Araya and Nobutaka Mukumoto and Michihide Mitsumori and Teruki Teshima",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.ijrobp.2008.08.067",
language = "English",
volume = "74",
pages = "759--765",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer

T2 - Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

AU - Ogawa, Kazuhiko

AU - Nakamura, Katsumasa

AU - Sasaki, Tomonari

AU - Onishi, Hiroshi

AU - Koizumi, Masahiko

AU - Shioyama, Yoshiyuki

AU - Araya, Masayuki

AU - Mukumoto, Nobutaka

AU - Mitsumori, Michihide

AU - Teshima, Teruki

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Purpose: To analyze retrospectively the results of external beam radiotherapy for clinically localized hormone-refractory prostate cancer and investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcomes after radiotherapy. Methods and Materials: Eighty-four patients with localized hormone-refractory prostate cancer treated with external beam radiotherapy were retrospectively reviewed. The total radiation doses ranged from 30 to 76 Gy (median, 66 Gy), and the median follow-up period for all 84 patients was 26.9 months (range, 2.7-77.3 months). Results: The 3-year actuarial overall survival, progression-free survival (PFS), and local control rates in all 84 patients after radiotherapy were 67%, 61%, and 93%, respectively. Although distant metastases and/or regional lymph node metastases developed in 34 patients (40%) after radiotherapy, local progression was observed in only 5 patients (6%). Of all 84 patients, the median nPSA12 in patients with clinical failure and in patients without clinical failure was 3.1 ng/mL and 0.5 ng/mL, respectively. When dividing patients according to low (<0.5 ng/mL) and high (≥0.5 ng/mL) nPSA12 levels, the 3-year PFS rate in patients with low nPSA12 and in those with high nPSA12 was 96% and 44%, respectively (p < 0.0001). In univariate analysis, nPSA12 and pretreatment PSA value had a significant impact on PFS, and in multivariate analysis nPSA12 alone was an independent prognostic factor for PFS after radiotherapy. Conclusions: External beam radiotherapy had an excellent local control rate for clinically localized hormone-refractory prostate cancer, and nPSA12 was predictive of clinical outcomes after radiotherapy.

AB - Purpose: To analyze retrospectively the results of external beam radiotherapy for clinically localized hormone-refractory prostate cancer and investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcomes after radiotherapy. Methods and Materials: Eighty-four patients with localized hormone-refractory prostate cancer treated with external beam radiotherapy were retrospectively reviewed. The total radiation doses ranged from 30 to 76 Gy (median, 66 Gy), and the median follow-up period for all 84 patients was 26.9 months (range, 2.7-77.3 months). Results: The 3-year actuarial overall survival, progression-free survival (PFS), and local control rates in all 84 patients after radiotherapy were 67%, 61%, and 93%, respectively. Although distant metastases and/or regional lymph node metastases developed in 34 patients (40%) after radiotherapy, local progression was observed in only 5 patients (6%). Of all 84 patients, the median nPSA12 in patients with clinical failure and in patients without clinical failure was 3.1 ng/mL and 0.5 ng/mL, respectively. When dividing patients according to low (<0.5 ng/mL) and high (≥0.5 ng/mL) nPSA12 levels, the 3-year PFS rate in patients with low nPSA12 and in those with high nPSA12 was 96% and 44%, respectively (p < 0.0001). In univariate analysis, nPSA12 and pretreatment PSA value had a significant impact on PFS, and in multivariate analysis nPSA12 alone was an independent prognostic factor for PFS after radiotherapy. Conclusions: External beam radiotherapy had an excellent local control rate for clinically localized hormone-refractory prostate cancer, and nPSA12 was predictive of clinical outcomes after radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=67049107507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049107507&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.08.067

DO - 10.1016/j.ijrobp.2008.08.067

M3 - Article

VL - 74

SP - 759

EP - 765

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -